Zensar Technologies Limited (BOM:504067)

Inozyme Pharma Ratios and Metrics

Market cap in millions INR. Fiscal year is April - March.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 6, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Market Capitalization	178,438	159,226	137,204	62,040	83,129	61,876
Market Cap Growth	13.38%	16.05%	121.15%	-25.37%	34.35%	217.38%
Enterprise Value	159,744	145,603	125,599	51,986	76,415	56,974
Last Close Price	785.30	692.01	590.81	264.38	347.59	257.23
PE Ratio	26.67	24.50	20.63	18.94	19.97	20.63
Forward PE	24.41	22.12	21.39	17.96	18.23	14.40
PS Ratio	3.32	3.02	2.80	1.28	1.96	1.64
PB Ratio	4.38	3.91	3.85	2.09	3.09	2.61
P/TBV Ratio	5.78	5.16	4.99	2.91	4.58	3.87
P/FCF Ratio	-	30.15	21.93	9.16	29.81	7.56
P/OCF Ratio	-	28.18	21.37	8.69	24.76	7.21
PEG Ratio	1.68	2.81	0.72	2.27	0.84	0.45
EV/Sales Ratio	2.97	2.76	2.56	1.07	1.80	1.51
EV/EBITDA Ratio	18.98	18.41	15.07	10.69	12.26	9.34
EV/EBIT Ratio	21.39	19.93	16.84	14.07	14.72	11.00
EV/FCF Ratio	-	27.57	20.07	7.67	27.40	6.96
Debt / Equity Ratio	0.03	0.03	0.05	0.09	0.13	0.15
Debt / EBITDA Ratio	0.15	0.15	0.21	0.50	0.49	0.52
Debt / FCF Ratio	-	0.24	0.30	0.40	1.20	0.43
Asset Turnover	-	1.08	1.12	1.22	1.17	1.08
Quick Ratio	-	3.66	2.89	2.60	2.63	2.59
Current Ratio	-	3.76	3.04	2.70	2.74	2.70
Return on Equity (ROE)	-	17.03%	20.34%	11.57%	16.67%	13.69%
Return on Assets (ROA)	-	9.30%	10.63%	5.80%	8.92%	9.21%
Return on Capital (ROIC)	11.75%	11.50%	13.33%	7.36%	11.30%	11.60%
Return on Capital Employed (ROCE)	-	17.00%	19.70%	11.30%	17.20%	19.20%
Earnings Yield	3.78%	4.08%	4.85%	5.28%	5.01%	4.85%
FCF Yield	-	3.32%	4.56%	10.92%	3.36%	13.23%
Dividend Yield	1.66%	1.88%	1.52%	1.89%	1.44%	1.40%
Payout Ratio	-	31.41%	18.74%	34.55%	21.16%	9.03%
Buyback Yield / Dilution	-0.22%	-0.09%	-0.35%	0.16%	-0.12%	0.34%
Total Shareholder Return	1.44%	1.79%	1.17%	2.05%	1.32%	1.74%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.